Less than eight months after nabbing a 50% share of hot AstraZeneca drug Lynparza, Merck is back with another partnership—this time on Eisai’s Lenvima.
Trogarzo (ibalizumab-uiyk) is the first HIV therapy with a novel mechanism of action in more than 10 years.
Samsung BioLogics is well on its way to becoming the world's largest contract manufacturer.
Daiichi Sankyo, which has struggled since losing exclusivity for its blood pressure drug Benicar, is cutting another 280 jobs in the U.S.
Shionogi's Roche-partnered Xofluza, a one-time, single-dose regimen, probably won't win U.S. approval till next winter.
After two refusals from Sanofi to provide a refund for the Dengvaxia program, officials in the Philippines say they are getting ready to sue.
“Agreeing to refund the used doses of Dengvaxia would imply that the vaccine is ineffective, which is not the case,” said Sanofi.
AstraZeneca made deals with China's Alibaba and Tencent as the British drugmaker reported double-digit growth in the country.
Ready to challenge GlaxoSmithKline and Merck, India's Bharat Biotech has won WHO prequalification for its rotavirus vaccine Rotavac.
Mylan and Biocon have won an EU recommendation for their Lantus biosimilar after overcoming manufacturing concerns that forced a delay last summer.
U.S biotech Evolus alerted investors that FDA concerns with a Daewoong plant in South Korea that will make its Botox copy could delay its approval.